Tonix Pharmaceuticals (NASDAQ:TNXP) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note issued to investors on Monday morning. The firm issued a hold rating on the stock.

Tonix Pharmaceuticals Trading Down 4.4 %

NASDAQ TNXP opened at $0.39 on Monday. Tonix Pharmaceuticals has a 52-week low of $0.12 and a 52-week high of $14.08. The firm has a 50-day moving average price of $0.22 and a 200 day moving average price of $0.41. The stock has a market capitalization of $72.01 million, a P/E ratio of -0.01 and a beta of 2.23. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($2.03) by $1.80. The business had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Equities research analysts expect that Tonix Pharmaceuticals will post -17.63 EPS for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.